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TT-232 is a structural derivative of the peptide hormone somatostatin with selective anti-
proliferative and anti-inﬂammatory properties. It has a strong anti-tumour activity both
in vitro and in vivo on a wide range of tumour models and induces apoptosis. Its anti-tumour
activity is mediated through the SSTR1 receptor and by the tumour speciﬁc isoform of
pyruvate kinase. TT-232 has been shown to be a potent neurogenic inﬂammation inhibitory,
anti-inﬂammatory and analgesic agent with a broader spectrum than presently available anti-
inﬂammatory/analgesic drugs. In animal models it is eﬀective against neurogenic inﬂammation
and blocks neuropathic hyperalgesia where COX-1 or COX-2 inhibitors (e.g. diclofenac or
meloxicam) proved ineﬀective. TT-232 has passed phase I clinical trials without toxicity and
signiﬁcant side eﬀects. Human phase II eﬃcacy studies are ongoing in melanoma indication.
Two more oncological indications and phase II clinical trials in inﬂammatory diseases,
including rheumatoid arthritis and burn injuries are in preparation. This compound has the
perspective to become the ﬁrst drug in molecularly targeted therapy of inﬂammation where a
combined eﬀect of anti-inﬂammatory, analgesic and neurogenic inﬂammation inhibiting
activity can be achieved.
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inﬂammatory activity; analgesic activity; clinical development.
INTRODUCTION
TT-232 (DPhe-Cys-Tyr-DTrp-Lys-Cys-Thr-NH2)
is a structural analogue of somatostatin, an endoge-
nous hormone with signiﬁcant anti-proliferative,
anti-inﬂammatory and neurogenic inﬂammation
inhibitory activity (Keri et al. 1993a, b; Helyes et al.
2000, 2004). In contrast to the parent hormone and
its ‘traditional’ analogues, this compound has strong
and selective anti-proliferative potential without
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clearance; CNS, central nervous system; COX, cyclooxigenase;
DTIC, dacarbazine; GABA, gamma-aminobutyric acid; GLP,
good laboratory practice; Gly, glycine; i.m., intramuscular; i.v.,
intravenous; LAA, lipo-amino acid; LD50, lethal dose 50%; LS,
liposaccharide; MM, malignant melanoma; MRT, mean residence
time; NOAEL, no observed adverse eﬀect level; s.c., subcutaneous;
SAA, sugar amino acid; SSTR1, somatostatin receptor type-1;
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elimination half-life; ThR, threonine; Trp, tryptophan.
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the wide-ranging endocrine side-eﬀects, including
inhibition of insulin secretion provoking diabetes.
The molecule has been shown to have unique
conformational characteristics (Jaspers et al. 1994;
Simon et al. 2004), selective binding properties to the
1st and 4th subtypes of somatostatin receptors
(SSTR1 and 4, Jing et al. and Patel unpublished
results) and to the intracellular receptor: pyruvate
kinase M2 (Stetak et al. 2001, 2004). No presently
marketed drug or drug-candidate in clinical trials has
a comparable molecular mechanism and eﬃcacy
proﬁle on these new pharmaceutical drug-targets in
the therapy of inﬂammation.
Somatostatin and its analogues have attracted
intense attention in drug development pipelines and
reached clinical application in the 1990s. The parent
compound, Somatostatin is a naturally occurring
tetradecapeptide hormone produced mostly by the
hypothalamus and the pancreas. However, it is
widely expressed in other parts of the central ner-
vous system (Gamse et al. 1981) and the peripheral
tissues as well in its 14 and 28 amino acid-contain-
ing forms (Patel et al. 1995; ten Bokum et al. 2000).
It is a general inhibitor of endocrine signalling
antagonizing the release of several pituitary and
intestinal factors that are involved in the regulation
of cellular functions including proliferation, motility
and secretion. Several of these factors are involved
in the regulation of tumour cell proliferation and in
inﬂammatory processes. The therapeutic use of
native somatostatin is limited by its broad range of
eﬀects and also by its very short (3 min) plasma half
life (ten Bokum et al. 2000). Analogues of somato-
statin have already been used in clinical practice but
many follow-up molecules are still in exploratory
phase and under clinical development (Fig. 1).
Sandostatin (octreotide DPhe-Cys-Phe-DTrp-Lys-
Thr-Cys-Thr-ol), its long-acting release formulation
Sandostatin LAR and its radiolabelled form Oct-
reoScan, Somatuline (lanreotide), NeoTect 99mTc
(depreotide) have been marketed worldwide,
whereas Sanvar/Octastatin (vapreotide) have already
completed phase III clinical trial on esophageal
variceal bleeding. In addition, there are many other
peptide and non-peptide analogues at various stages
of development. LAN-7 was synthesised at the
University of California, Oakland, an analogue of
TT-232 in which a lanthionine bridge replaces the
disulphide bridge between the two cysteines, making
the peptide more stable. LAN-7 is being evaluated
as a potential anti-tumour agent (Zheng et al. 1997).
Similar to TT-232, LAN-7 has also been shown to
have signiﬁcant anti-proliferative eﬀects on a num-
ber of human tumour cell lines, with the two
compounds exhibiting similar potencies without
concomitant toxicity on normal human haemato-
poietic progenitor cells.
Historically, development of TT-232 was started
as a signal-transduction inhibitor drug candidate
targeting oncological applications in 1992, while
increasing evidence on the molecular pharmacology
of its action along with extensive preclinical efﬁcacy
studies have put the anti-inﬂammatory indication
also into the front line of present development efforts.
The preclinical dossiers in both indications have been
completed. Primary oncological disease targets were
set to malignant melanoma (MM), breast cancer (BC)
and chronic lymphoid leukaemia (CLL). After suc-
cessful phase I clinics on healthy volunteers, the ﬁrst
human phase II (safety and dose-ﬁnding efﬁcacy)
trial using TT-232 as a single agent in late stage dis-
seminated MM was completed. This conﬁrmed pre-
dicted safety and showed promising clinical response.
Add-on trials on MM and BC are in progress and
under preparation, respectively.
The overall results of the numerous safety studies
showed that TT-232 is a molecule of low toxicity: no
accumulation, allergic or mutagenic effects were seen.
The most signiﬁcant feature is that TT-232 does not
affect vital function or morphology of tissues as most
cytotoxic agents used in the baseline treatment of
inﬂammatory disorders (e.g. methotrexate in rheu-
matoid arthritis) and classical anti-cancer agents do.
Minor side effects like hypotension and some local
reactions after intravenous administration in periph-
eral vessels did not require medical attention.
TT-232 has been shown to be a potent neurogenic
inﬂammation inhibitory, anti-inﬂammatory and
analgesic agent with a broader spectrum than pres-
ently available anti-inﬂammatory/analgesic drugs. In
animal models it is effective against neurogenic
inﬂammation and blocks neuropathic hyperalgesia
where COX-1 or COX-2 inhibitors (e.g. diclofenac or
meloxicam) proved ineffective. Predicted indication
proﬁle of TT-232 is in line with ‘disease-modifying’
agents in the baseline therapy of ‘autoimmune’
inﬂammatory disorders, where classical anti-cancer
agents have proven success in the past 20 years (see
methotrexate, azathioprine, etc.). Acting on the
peripheral sensory neurons, this molecule has a strong
analgesic effect too, which proved signiﬁcantly greater
than that of non-steroid anti-inﬂammatory agents
(e.g. diclofenac) and comparable to morphine in var-
ious animal models. After completed human phase I
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safety trials, phase II clinical studies are now planned
in two of the most promising disease indications,
rheumatoid arthritis and burn injuries.
ANTI-NEOPLASTIC ACTIVITY OF TT-232
It has been demonstrated, that TT-232 in
20–30 lM dose range inhibits proliferation (50–95%)
and induces apoptosis on 20 different human tumour
cell lines (Keri et al. 1996, 2004; Tovari et al. 1998;
Tompa et al. 2000; Szende et al. 2003). TT-232 has
been tested and found eﬀective in 60 various human
tumour cell lines by The National Cancer Institute,
NIH, USA: 100 lM of TT-232 had a strong anti-
proliferative eﬀect on the majority of cell lines
(unpublished results), while the ‘traditional type’
somatostatin analogues (e.g. TT-248 and octreotide)
had practically no eﬀect on the same cell lines.
TT-232 inhibited in vitro proliferation of D10,
205, LSD22, Me8, IGR3 (Siegrist et al. 1989), HBL
(Siegrist et al. 1994) and SK-MEL1 human melano-
ma cells when tested in a dose range of 0.1–30 lg/ml
Fig. 1. Structures of somatostatin and its analogues.
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TT-232 (Schwab et al. 2001): proliferation of all the
cell-lines were inhibited by 100% at 30 lg/ml, whilst
the 205 cells showed even somewhat greater sensi-
tivity, with an IC50 value of 10 lg/ml. The anti-pro-
liferative eﬀect of TT-232 was also demonstrated on
hepatocellular carcinoma cell lines (Diaconu et al.
1999) (including diﬀerentiated and dediﬀerentiated,
drug sensitive and multidrug-resistant hepatomas)
and on human pancreatic cancer cell lines along with
a strong apoptotic response (Lee et al. 2002). In
addition, treatment of M1- and WM-melanoma and
K-562 leukaemia cells with 10 lg/ml TT-232 resulted
in a distinct increase of the apoptotic index (70, 4–5
and 60· respectively).
In vivo Studies
A great number of in vivo experiments carried out
at diﬀerent cancer research centers using various
tumour types were conducted to deﬁne the in vivo tu-
mour growth inhibitory properties of the molecule.
Greatest eﬃcacywas seen in the diﬀerent breast, colon,
melanoma, sarcoma and lymphoma tumour models
(Table I), and among them, the melanoma, breast and
lymphoma human xenografts were found to be the
most responsive. TT-232 showed strong tumour
growth inhibition at a daily dose in the lowmicromolar
range that resulted in up to 40% clearance of the
transplanted tumour and long-term survival.
Extensive studies have also targeted the relation-
ship of the efﬁcacy and the administration route/
duration of treatment. Comparative experiments
conﬁrmed that continuous, intravenous long-term
administration (14 days or more) is associated with
the best treatment response in all in vivo models
studied. However, minor diﬀerences were detected
between subcutaneous and intravenous administra-
tion routes that warrant further investigations.
Extrapolating these results for the human clinical
application, continuous infusion therapy can be
regarded as the most promising alternative in terms
of ease of application and predicted efﬁcacy. On the
other hand novel formulations, similar to the long
acting, slow release forms of octreotide and lanreo-
tide are promising alternatives for future develop-
ment in view of the almost equivalent efﬁcacy and
advantages associated with once-a-month injection
application form.
Combination Studies
TT-232 was applied together with Etoposide and
DTIC (dacarbazine) on human melanoma and lym-
phoma xenografts and a melanoma metastasis model
in mice (Szende et al. 2003) in order to investigate the
eﬀect of TT-232 on tumour growth when applied
together with known chemotherapeutic agents to
mimic the combination chemotherapy in humans. In
HT-18 melanoma xenografts, a combination of 1 mg/
kg TT-232 with 30 or 60 mg/kg DTIC (administered
daily) resulted in a stronger inhibitory eﬀect com-
pared to TT-232 or DTIC alone. Administration of
Table I. Tumour Growth Inhibitory Eﬀect of TT-232 at Various Routes of Administration in Experimental Tumours of Human or Animal
Origin Implanted into Mice









MDA-MB-23 Breast (H) 30 s.c. 0.500 80 38 ++++ Keri et al. 1996
MXT Breast (H) 28 s.m.p. 0.030 62 0 ++ Tejeda et al. 2003
MXT Breast (H) 28 i.m.p. 0.030 70 0 ++ Tejeda et al. 2003
Colon-26 Colon 28 s.m.p. 0.030 57 0 + Tejeda et al. 2003
Colon-26 Colon 28 i.m.p. 0.030 60 0 ++ Tejeda et al. 2003
205 Melanoma (H) 14 s.c. 0.030 50 25 ++++ Schwab et al. 2001
B16 Melanoma 20 s.c. 1.000 100 0 ++++ Szende et al. 2003
B16 Melanoma 19 s.c. 0.750 50 0 ++ Keri et al. 1996
D-10 Melanoma (H) 14 s.m.p. 0.150 50 13 ++++ Schwab et al. 2001
HT-18/DTIC Melanoma (H) 21 s.c. 1000 63 0 ++ Szende and Keri, 2003
S-180 Sarcoma 14 s.m.p. 0.030 69 40 ++++ Tejeda et al. 2000
S-180 Sarcoma 14 i.m.p. 0.030 92 40 ++++ Tejeda et al. 2000
p388 Lymphoma 28 s.m.p. 0.030 80 20 +++ Tejeda et al. 2003
p388 Lymphoma 28 i.m.p. 0.030 82 20 +++ Tejeda et al. 2003
HT-58/etoposide Lymphoma (H) 21 s.c. 1.000 97 0 ++++ Szende et al. 2003
Lewis Lung metastasis 14 i.v. 0.500 70 0 ++ Keri et al. 1993a
+ = weak eﬀect; ++ = moderate eﬀect; +++ = strong eﬀect; ++++ = very strong eﬀect; s.m.p. = subcutaneous mini pump;
i.m.p. = intravenous mini pump.
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1 mg/kg/day TT/232 alone or in combination with 30
or 60 mg/kg DTIC resulted in a signiﬁcant decrease
of the number of lung metastasis in the B16 mouse
melanoma muscle-lung metastasis model. However,
TT-232 did not increase the eﬀect of DTIC on the
primary tumour. In HT-58 lymphoma nearly 50%
growth inhibition was achieved by daily treatment
with 1 mg/kg TT-232, which corresponds to the eﬀect
of 5 mg/kg etoposide. The combination of TT-232
(1 mg/kg) and etoposide (5 mg/kg) proved to be
signiﬁcantly more eﬀective than TT-232 or etoposide
as a single treatment. Moreover, the very strong
tumour growth inhibitory eﬀect of 10 mg/kg etopo-
side could even be increased by the combination of
10 mg/kg etoposide with 1 mg/kg TT-232.
Clinical Studies
The 16 healthy volunteers involved in the human
phase I/a study tolerated doses of TT-232 up to
480 lg/kg without signiﬁcant side effects when
administered in weekly increasing single doses.
TT-232 was found to be non-toxic in the applied
doses. In some cases local vein irritating effect was
noticed (in a single case with vein occlusion), which
was attributed to the high concentration of the
TT-232 containing solvent. In order to avoid this side
effect, the injection for infusion must be diluted at
least 2.5 fold by 5% dextrose. Due to the low toxicity
and the lack of serious side effects of TT-232, maxi-
mal tolerable daily dose was not reached in the study.
In the human phase I/b study TT-232 was given
in 4 h long i.v. infusions of 480 lg/kg over 10 con-
secutive days in healthy volunteers. Plasma concen-
trations of TT-232 were reduced by approximately
80% 4 h after stopping the infusion and plasma
concentrations were below the quantitation limit in
each case after 20 h. As minor side effects superﬁcial
vein irritation and bradycardia was observed in some
cases but without medical signiﬁcance. Neither any
clinically relevant side effect, nor any cumulation of
TT-232 in the plasma could be found in this study.
An open-label, one group human phase II/a study
was carried out in patients with metastatic malignant
melanoma resistant to previous therapy to assess the
efﬁcacy and safety of TT-232. Patients were treated
with 4 h daily infusions of 480 lg/kg TT-232 for
7 days followed by a 7-day-wash-out period. Each
patient received four cycles of the experimental
therapy.
One patient had a dramatic regression of lymph
node metastases in the supraclavicular and axillary
regions. However, after 6 months of therapy he died
in meningeal relapse, without recurrence of metasta-
ses in the lymphatics. Stable disease was seen in 3/12
patients for at least 6-month and 8/12 patients had
progressive disease. The treatment was well tolerated
without signiﬁcant side effects during the examina-
tion period (Gyergyai et al. 2003).
ANTI-INFLAMMATORY, NEUROGENIC
INFLAMMATION INHIBITORY AND
ANALGESIC EFFECT OF TT-232
TT-232 has been found to inhibit both neurogenic
and non-neurogenic inﬂammation. The molecular
mechanism of the general anti-inﬂammatory activity
can be linked to the growth inhibition of activated
lymphocytes via either the SSTR-dependent cell cycle
block or the SSTR-independent rapid cell death and
to the inhibition of secretion of certain inﬂammatory
mediator cytokines.
SSTR4 and SSTR1 Play an Important Role in the
In vivo Anti-inﬂammatory Activity of TT-232
In the rat adjuvant arthritis model, SSTR3 and
SSTR4 receptor subtypes are overexpressed in the
immune system. In this model, octreotide, which had
high afﬁnity for SSTR2 and SSTR5 (Siehler et al.
1998), does not eﬀect the severity of the inﬂammation
(ten Bokum et al. 1999), but the daily administration
of TT-232 (2 · 100–500 lg/kg i.p.) throughout the
experimental period of 18 days dose-dependently
inhibits oedema and inﬂammatory mechanical
hyperalgesia (Pinter et al. 2002). Octreotide had also
no such eﬀect in mustard oil-induced neurogenic
inﬂammatory models, where TT-232 was proved to
be highly eﬀective (Helyes et al. 2001). Therefore, we
presume that SSTR4 – and less importantly also
SSTR1 – mediated signalling is responsible for the
anti-inﬂammatory action of somatostatin and
TT-232. Inhibition of tyrosine kinases by TT-232
(Keri et al. 1993b), is not likely to be a mechanism of
its anti-inﬂammatory and analgesic eﬀect, since a
potent tyrosine kinase inhibitor, genistein, failed to
inﬂuence the stimulated sensory neuropeptide
(P-substance, calcitonin gene-related peptide
(CGRP)) release (Pinter et al. 2002). On the other
hand, blocking the action of G-protein-coupled
receptors by pertussis toxin, prevents the inhibition
induced by TT-232 on the release of sensory neuro-
peptides in response to electrical ﬁeld stimulation of
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sensory ﬁbres in the rat trachea in vitro (Pinter et al.
2002; Helyes et al. 2003).
TT-232 Inhibits the Proliferation of Activated B- and
T-lymphocytes
The possible anti-proliferative effect of TT-232
was assessed on stimulated T- and B-lymphocyte
cultures. The rate of proliferation was determined by
3H-thymidine incorporation assay. After 48 h incu-
bation, IC50 values ranged between 10 and 20 lg/ml
in diﬀerent cell cultures. Interestingly for B-lympho-
cytes the average IC50 value was 13 lg/ml, while for
T-lymphocytes it was 6.6 lg/ml (unpublished results)
(Figs. 2 and 3). This assay did not reveal whether the
mechanism of growth inhibition was cell cycle block
or apoptosis. However, since cells were incubated
continuously with TT-232, SSTR-independent
induction is the most likely mechanism. This is fur-
ther supported by the observation that octreotide, the
eﬀective inhibitor of SSTR2, SSTR mainly expressed
by human lymphocytes, did not inhibit lymphocyte
proliferation.
In vivo Anti-inﬂammatory, Analgesic and Neurogenic
Inﬂammation Inhibitory Activity of TT-232
TT-232 is a potent anti-inﬂammatory and anal-
gesic agent with a broader spectrum than the pres-
ently available anti-inﬂammatory/analgesic agents. In
animal models it is effective against neurogenic
inﬂammation and blocks neuropathic hyperalgesia
unlike COX-1 or COX-2 inhibitors e.g. diclofenac or
meloxicam which are ineffective in these respects. It is
about 100 times more potent analgesic than morphine
and its efﬁcacy is higher than that of diclofenac.
TT-232 is a potent anti-inﬂammatory agent in a series
of inﬂammatory models, and in addition it inhibits
neurogenic inﬂammation which can not be inhibited
by any of the known non-steroidal agents. TT-232
did not produce mucosal ulcerations in the stomach
and duodenum of the rat up to 1000-times higher
dose range (0.5–5 mg/kg i.v.) than its doses which
induce analgesic/anti-inﬂammatory effects (Pinter
et al. 2002).
Neurogenic and non-neurogenic components
simultaneously take part in most of the inﬂammatory
processes, and neurogenic inﬂammation plays sig-
niﬁcant role in the pathogenesis of rheumatoid
arthritis, and several other diseases and also in
adjuvant arthritis in the rat, and murine delayed-type
hypersensitivity reactions. Daily s.c. pre-treatment of
rats with doses of TT-232 which inhibited neurogenic
inﬂammation for 6 ± 16 h diminished also the
development of Freund adjuvant-induced bilateral
arthritis. It has been described in several experimental
models that somatostatin suppresses a number of
immune functions among others the release of pro-
inﬂammatory cytokines, lymphocyte proliferation,
and immunoglobulin production. In the Freund
adjuvant arthritis model activation of T-cell subtypes
by Mycobacterium crossreacts with articular tissues
causing in this way joint destruction and enhance-
ment of local immune responses. The fact that this
type of systemic chronic inﬂammatory response is
also inhibited by somatostatin analogue which devoid
of endocrine eﬀects opens new horizons for devel-
opment of broad spectrum anti-inﬂammatory
agents which are eﬀective also against neurogenic
inﬂammation. TT-232 is a promising, eﬀective, stable
and selective somatostatin analogue for parenteral
Effect of Octreotide and TT232
















Fig. 2. Eﬀect of octreotide and TT-232 on T-cell proliferation.
Effect of Octreotide and TT232
















Fig. 3. Eﬀect of octreotide and TT-232 on B-cell proliferation.
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application. It is proposed as a lead molecule for a
new class of anti-inﬂammatory, analgesic agents.
This favourable scope of action of TT-232 is
attributed to a selective action on SSTR1 and
SSTR4 somatostatin receptors, while the endocrine
effects are mediated by activation of SSTR2, SSTR3
and SSTR5 receptors. Thus based on a series of in
vitro and in vivo eﬃcacy experiments we completed
the preclinical studies with TT-232 for phase I clin-
ical investigations, and will start the phase I/b and
phase II clinical studies for burned patients (where
strong analgesic and neurogenic inﬂammation inhi-
bition is required) and rheumatoid arthritis indica-
tions. Rheumatoid arthritis aﬀects about 0.5–1% of
the population in the developed world and the
strong neurogenic inﬂammatory part of arthritis
cannot be treated with any of the presently used
drugs. The therapeutic eﬀect of native somatostatin
on rheumatoid arthritis has been proved, but its
therapeutic application is limited by the endocrine
side eﬀects and by the short plasma half life. Our
aim is to develop TT-232 as a broad spectrum
analgesic, anti-inﬂammatory and neurogenic inﬂam-
mation inhibiting agent for severe conditions in
burned patients and rheumatoid arthritis. Additional
indications might include asthma, certain kind of
allergies and sport accidents where strong analgesic
and anti-inﬂammatory eﬀect has to be quickly
achieved via injecting the drug.
Tables II–IV summarises the eﬀect of TT-232 on
various neurogenic inﬂammatory, arthritis and anal-
gesic models.
PRECLINICAL STUDIES
The active ingredient is synthetised with a pat-
ented technology on solid phase (Lifferth et al. 2000).
TT-232 has proved a stable molecule, no decompo-
sition was detected in lyophilised form at 25C when
protected from light for 3 years The 0.1% injection
solution, kept at 4C, was stable for at least 2 years,
showing only 1% decrease in the TT-232 content.
Toxicity Studies
Toxicology and other safety studies were carried
out at the institute for drug research (IDR) in Hun-
gary between 1996 and 1999 in accordance to good
laboratory practice (GLP) guidelines. Toxicology,
immunogenicity, teratology, mutagenicity and safety
pharmacology were performed (Tables V and VI).
Overall results of the numerous toxicity studies
showed that TT-232 has practically no toxic eﬀects in
the clinically relevant dose range. It shows no toxic
accumulation, proved not to be an allergen and had
no mutagenic eﬀects. The most signiﬁcant feature is
that TT-232 does not aﬀect the function or mor-











Mustard oil Paw i.p. 10 lg/kg 64 SRIF
(10 lg/kg):




i.v. 20 lg/kg 80 DICLO
(5–100 mg/kg)
No eﬀect





Capsaicin Ear s.c. 20 lg/kg 80 DICLO
(5–20 mg/kg)














500 nM SP 36 Helyes et al. 2001
CGRP 48
SRIF 29
Experiments were carried out mainly in rats,the capsaicin induced plasma extravasation was examined in mice, SRIF = somatostatin;
OCTR = octreotide; DICLO = diclofenac; MELOX = meloxicam.
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phology of tissues as most cytotoxic agents do (e.g. in
haematopoietic and immune-competent tissues and
small intestinal mucosa, etc). Minor side eﬀects de-
tected include local irritative eﬀect and systemic
blood pressure lowering eﬀect.
Safety Pharmacology
Safety pharmacology studies were performed
in the following models: behavioural studies on
mice, potentiation of hexobarbital-Na narcosis on
mice, inhibition of electroconvulsive shock on mice,
motility study on the rat, effect on the body tem-
perature of the rat, gastrointestinal studies on mice,
ulcerogenecity study on the rat, inﬂuence of diuresis
on the rat, blood circulating studies on anaesthetised
rats and phenylquinone writhing test on mice.
No CNS-related toxicity e.g. change in behaviour,
motility or temperature was found in the 3 and
10 mg/kg i.v. dose levels. It has no anti-convulsive,
narcoses potentiating, and ulcerogenic activity.
TT-232 had slight diuretic effect and mean arterial
pressure of anaesthetised rats was dose-dependently
decreased at the 10 mg/kg dose level.
Mutagenicity Studies
Mutagenicity of TT-232 was evaluated in the
Salmonella typhimurium microsome mutation test in
the presence and absence of a mammalian metabolic
activation system and TT-232 can be considered not
mutagenic.
Reproduction Toxicology Studies
Pilot pre-implantation and teratology studies in
rats: female Wistar rats were treated with 1, 3 and
10 mg/kg daily doses of TT-232 on days 1–6 (pre-
implantation) and 7–16 (teratology) of pregnancy.
The applied doses had no detectable inﬂuence on the
pre-implantation and intrauterine development of
embryos and were not teratogenic.
Pilot pre- and post-natal studies in rats: no eﬀects
were seen up to doses of 10 mg/kg of TT-232 in
mothers including duration of pregnancy, delivery
process, intra- and extra-uterine mortality rate of still
births, gender of the oﬀspring, and post-natal devel-
opment. No macroscopic changes were detectable at
the autopsy of oﬀspring.
Teratology studies of TT-232: The objective of the
studies was to assess the eﬀect of TT-232 on the
course and outcome of pregnancy. It was intended to
provide general information concerning the eﬀects of
pre-natal exposure on the pregnant animals and on
the developing conceptuses during the organogenesis
after intravenous administration of TT-232 at four
(rats) and three (rabbits) dose levels. The clinical
symptoms, mortality, necropsy ﬁndings, body weight
gain and reproduction data of the mothers were
evaluated. The body weight of the foetuses and
weight of placenta were measured, and the external,
visceral and skeletal abnormalities of foetuses were
recorded and evaluated. Data showed that TT-232 up
to 15 mg/kg/day has not teratological eﬀect in rats
and rabbits.
Eﬀect on spermatogenesis in a 28-day study in rats:
TT-232 did not cause alterations of sperm parameters
including motility, morphology and counts in the
doses applied (up to 10 mg/kg) conﬁrming no eﬀect
Table V. LD50 and ALD Values in Diﬀerent Species
















Rat 28 days 1 3 mg/kg 10 None 10 None Renal tubular degeneration
+ local irritation at injection site
Rabbit 28 days 0.5 2 mg/kg 6 None 6 None Renal tubular degeneration
+ local irritation at injection site
Rat 90 days 2 n.a. 6 None 6 None
Dog 90 days 0.5 n.a. 2 none 6 2 Reversible elevation of liver transaminases,
BUN, creatinine in plasma
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of TT-232 to the spermatogenesis in rats after
28 days.
ADME Studies
In order to study the fate of TT-232 in the living
organism, a 14C-labelled derivative was synthetised
with a very high speciﬁc activity (489.1 kBq/mg) at
the Institute of Isotopes, Budapest, Hungary. The site
of the labelled 14C-atom was the a position of the
D())phenylalanine. Both chemical and radiochemical
purity were above 95%. On the basis of statistical
calculations it was established, that after a single
2 mg/kg intravenous administration of TT-232 a
signiﬁcant gender-dependent diﬀerences in the main
characteristic pharmacokinetic parameters (t1/2,
AUD, AUDe, MRT and Cltot) were not found.
Absorption
Absorption of 2 mg/kg 14C-labelled TT-232
administered subcutaneously and intraperitoneal was
rapid and signiﬁcant, resulting in high bioavailability.
However, at a 20 mg/kg subcutaneous and intra-
peritoneal dose the absorption was rapid but limited.
Oral bioavailability is poor. Best, not limited bio-
availability can be achieved via intravenous admin-
istration where 20 mg/kg TT-232 results in 30 lg/ml
peptide in the circulation for about 2 h. Indepen-
dently from the administration route (i.v., s.c. or i.p.),
the blood concentration were about the half of the
corresponding plasma levels indicating a very weak
binding of radioactivity to blood cells.
Distribution
Approximately 60–70% of 14C-TT-232 was
bound to plasma proteins in reversible manner in
the in vitro setting. The strong, irreversible binding
of radioactivity to plasma proteins may be respon-
sible for extreme long plasma elimination half-life
(>100 h).
Organ levels of total radioactivity increased in
time after i.v. administration of 2 mg/kg TT-232.
Highest organ levels were found in the liver and
gastrointestinal tract (60%) within a few hours after
administration. High organ levels were found in the
kidneys as well, reﬂecting the prominent role of
urinary elimination of radioactivity. Low concen-
trations in brain (about 0.1 lgE/g) indicated weak
penetration of radioactivity through the blood–brain
barrier.
Metabolism
Ten minutes after administration the main part of
radioactivity seems to be TT-232. At 2 h after intra-
venous treatment the parent compound could not be
detected in plasma. The main detectable component
seems to be the free, labelled D-phenylalanine. At 3
and 6 h after treatment the plasma samples – inde-
pendently from the administration route – contained
radioactivity in protein bound form only.
Unchanged TT-232, D-phenylalanine, one fur-
ther main metabolite of TT-232 and minor metabo-
lites (that do not bind to proteins) were excreted by
urine. The main part of radioactivity excreted with
urine was the original compound.
The main radioactive component in bile (inde-
pendently from time) seemed to be TT-232. Although
approximately 50–60% of the administered dose was
excreted by bile mainly during the ﬁrst 2 h, at later
time points, unchanged peptide could not be found
either in plasma (as the sign of reabsorption in un-
changed form) or in faeces (as sign of elimination). It
can be supposed, that the radioactivity had to be
decomposed in the intestines by digesting enzymes,
and a part of radioactivity reabsorbed and trans-
ported via portal vein to liver where further metabolic
transformations might also be possible.
Excretion
The ﬁrst phase of elimination of total radioac-
tivity was rapid. Most of the radioactivity adminis-
trated was excreted in the ﬁrst 4 h in bile and 6–12 h
in urine. During the 1-week collection period 30% of
radioactivity was excreted with urine and 10% in
faeces. Most of the missing radioactivity was found in
cadaver (40%).
The main pathway of elimination is by bile
(about 50–60% of dose administered) within a few
hours. The amount of radioactivity excreted in bile
got into the intestines and was transformed to
fragments. Because of the enterohepatic recircula-
tion most of the radioactivity excreted with the bile
does not get into the faeces but gets back to the
systemic blood circulation – resulting in relatively
high blood and plasma levels after the 1st post-
treatment hour.
Elimination of radioactivity from plasma is slow
(t1/2 is approximately 100 h) and an important part of
radioactivity remained in the animals. This phe-
nomenon is most probably due to the radioactivity of
the 14C-labelled D())phenylalanine or its fragments.
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TT-232 ANALOGUES AND FOLLOW-UP
MOLECULES (LIPO-AMINO ACIDS,
SUGAR-CONTAINING AMINO ACIDS)
In order to investigate structure – activity rela-
tionships we have synthesised a big series of TT-232
analogues, systematically changing various amino
acids in the structure, (earlier TT-232 was developed
by systematic changes or ‘leave out’ in a traditional
octapeptide somatostatin analogue). A series of these
analogues is shown in Table VII. Some of these
analogues had comparable anti-proliferative effect as
TT-232, but none of them was better, and none of
them had better physicochemical or bioavailability
parameters. In order to improve bioavailability we
have synthesised lipo-amino acid derivatives and
sugar-amino acid containing derivatives.
Lipo-Amino Acid Containing TT-232 Analogues
A lipo-amino acid (LAA) based drug-delivery
system was used to try to enhance oral availability of
the drug-candidate. The method involves combining
the peptide or drug with an LAA moiety (Fig. 4),
which acts as a carrier. LAAs combine the properties
of amino acids (NH2 and COOH groups) with dose
of lipids (hydrophobic side chains) to enhance passive
transfer via cellular membranes in a stable and bio-
logically active form (Gibbons et al. 1990; Toth
1994). LAAs are highly versatile molecules, their
length and degree of unsaturation, as well as, their
stereochemistry can be modiﬁed. They can be spe-
ciﬁcally tailored to transport a wide variety of pep-
tides or poorly absorbed drugs across the barriers
that normally inhibit absorption from the gut or into
the brain. Furthermore, peptides are released from
the LAA conjugate after absorption (i.e. the conju-
gate becomes the active moiety). Although conjuga-
tion of LAAs improves the lipophilicity necessary for
crossing biological membranes, it can have an ad-
verse eﬀect on the water solubility. The conjugate has
to show a certain degree of water solubility, to allow
absorption from the gastrointestinal tract, so lipo-
saccharides (LS) could improve this parameter.
LAA conjugates of TT-232 were synthesised with
modiﬁcations in the relative position, the number,
and the nature of the lipid and/or saccharide moieties
(Fig. 4). In vitro results conﬁrmed biological eﬃcacy
comparable to the parent compound. ADME studies
in CaCo-2 monolayers showed promising perme-
ability coeﬃcient Papp values (Papp ¼ 0:86 106)















Fig. 4. General formula of lipo-amino acid conjugates. X: H or
sugar moiety, Y: None or GlyGly or GABA, R1: disulphide bridge
or ACM, R2:H or LAA or sugar moiety.
Table VII. Structure of Traditional TT-232 Analogues
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1999). Analogues containing only lipo-amino acids
had the best activity (in the range of that of TT-232)
but solubility and bioavailability decreased even
compared to TT-232. A good permeability value
could be achieved only if liposaccharide was attached
to the molecule, but than the bioactivity decreased.
Our conclusion was that although the N and C-ter-
minal modiﬁcation of TT-232 with LAA or LS result
in amphipathic surfactant like molecules with im-
proved bioavailability, this changes decreased bioac-
tivity of the molecules. To improve physicochemical
properties of the parent compound an additional
approach was chosen where we incorporated novel
kind of sugar moieties into the parent peptide.
Sugar Amino Acid Containing TT-232 Analogues
Chimeras of the three big classes of biopolymers,
i.e. nucleic acids, proteins and carbohydrates, have
attracted great interest as both functional, and struc-
tural analogues in recent years, also because of their
potential application in drug design. Sugar amino
acids (SAAs) and their oligomers, which bridge car-
bohydrates and proteins, have also attracted much
interest from the early 1990s (Suhara et al. 1996;
Wessel et al. 1996; Lohof et al. 1999; Brittain et al.
2000). SAAs are sugar moieties containing at least one
amino- as well as at least one carboxyl-group (Fig. 5).
They allow among other modiﬁcations the replace-
ment of the naturally occurring, but synthetically
diﬃcult to generate, O-/N-glycosidic bonds by pep-
tidic bonds. This not only increases their enzymatic
stability, but facilitates the assembly of large, diverse
oligomer carbohydrate or peptidomimetic libraries by
solid phase techniques, as well.
SAA containing TT-232 analogues have been
shown to possess anti-proliferative and apoptotic
activity against both multidrug-resistant and sensitive
haepatoma carcinoma cells (Gruner et al. 2001). Four
analogues have IC50 values in the low lM range,
making them promising leads for chemotherapeutic
drug candidates. A big aromatic residue in the Thr10
position seems to be imperative for high anti-prolifer-
ative andapoptotic activity.Replacement of theD-Trp
with D-Bta (D-benzothienylalanine) resulted in ana-
logues with even higher biologic eﬃcacy. In view of the
non-proteinogenic properties of SAAs, these com-
pounds are very promising follow-up molecules with
increased stability and enhanced bioavailability. An
international patent has been ﬁled on these compounds
in collaboration with Novaspin Biotech GMBH.
FUTURE PERSPECTIVES
Within 2-year stime, TT-232 is expected to reach
proof-of-concept phase III. clinical trials in both
oncological and anti-inﬂammatory indications. Dur-
ing this time developments in topical administration
are planned.
One of the key elements of the development
process involves research on target theranostics:
molecule-targeted diagnostics to predict drug-efﬁcacy
and enabling a personalised treatment approach in
individual clinical cases.
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